Skip to main content
SpringerLink
Log in

Hepatitis Cvirus and Cardiomyopathy

  • Chapter
Cardiomyopathies and Heart Failure

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 248))

Abstract

Viral myocarditis may be caused by several different viruses, and evidence has accumulated linking viral myocarditis to the eventual development of dilated cardiomyopathy (DCM).1-3 Since some patients with myocarditis and DCM have elevated titers of antibody against coxsackievirus B3, it has been speculated that DCM is a long-term sequela of myocarditis caused by coxsackievirus B.4,5 However, a direct and conclusive proof is lacking.3 Using new molecular biological techniques, recent studies have implicated cytomegalovirus6 or adenovirus7 in the pathogenesis of DCM. On the other hand, the susceptibility to viral infection may be determined primarily by host factors. Therefore, racial diversity of patient populations and variable geographical distributions of the viruses may have to be considered when studying the etiology of myocarditis and DCM. It is also possible that yet unknown viruses contribute to the progression of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Matsumori A, Kawai C. An Animal Model of Congestive (Dilated) Cardiomyopathy: Dilatation and Hypertrophy of the Heart in the Chronic Stage in DBA/2 Mice with Myocarditis Caused by Encephalomyocarditis Virus. Circulation 1982; 66: 355–360.

    Article  PubMed  CAS  Google Scholar 

  2. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343: 1388–1398.

    Article  PubMed  CAS  Google Scholar 

  3. Dec GW, Fuster V. Idiopathic Dilated Cardiomyopathy. N Engl J Med 1994; 331: 1564–1575.

    Article  PubMed  CAS  Google Scholar 

  4. Woodruff JF. Viral myocarditis. Am J Pathol 1980; 101: 425–484.

    PubMed  CAS  Google Scholar 

  5. Muir P, Nicholson F, Tilzey AJ, et al. Chronic Relapsing Pericarditis and Dilated Cardiomyopathy: Serological Evidence of Persistent Enterovirus Infection. Lancet 1989; 1: 804–807.

    Article  PubMed  CAS  Google Scholar 

  6. Schonian U, Crombach M, Maser S, et al. Cytomegalovirus-Associated Heart Muscle Disease. Eur Heart J 1995; 16: 46–49.

    Article  PubMed  Google Scholar 

  7. Pauschinger M, Bowles NE, Fuentes-Garcia J, et al. Detection of Adenoviral Genome in the Myocardium of Adult Patients with Idiopathic Left Ventricular Dysfunction. Circulation 1999; 99: 1348–1354.

    Article  PubMed  CAS  Google Scholar 

  8. Lauer GM, Walker BD. Hepatitis C Virus Infection. N Engl J Med 2001; 345: 41–52.

    Article  PubMed  CAS  Google Scholar 

  9. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351–355.

    Article  PubMed  Google Scholar 

  10. Cerny A, Chisari FV. Pathogenesis of Chronic Hepatitis C: Immunological Features of Hepatic Injury and Viral Persistence. Hepatology 1999; 30: 595–601.

    Article  PubMed  CAS  Google Scholar 

  11. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C. Ann Intern Med 2000; 132: 296–305.

    PubMed  CAS  Google Scholar 

  12. Pascual M, Perrin L, Giostra E, et al. Hepatitis C Virus in Patients with Cryoglobulinemia Type II. J Infect Dis 1990; 162: 569–567.

    Article  PubMed  CAS  Google Scholar 

  13. Durand JM, Kaplanski G, Lefevre P, et al. Effect of Interferon-Alpha 2b on Cryoglobulinemia Related to Hepatitis C Virus Infection. J Infect Dis 1992; 165: 778–779.

    Article  PubMed  CAS  Google Scholar 

  14. Cacoub P, Lunel-Fabiani F, Du LT. Polyarteritis Nodosa and Hepatitis C Virus Infection. Ann Intern Med 1992; 116: 605–606.

    PubMed  CAS  Google Scholar 

  15. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic Sialadenitis of Sjögren’s Syndrome Associated with Chronic Hepatitis C Virus Liver Disease. Lancet 1992; 339: 321–323.

    Article  PubMed  CAS  Google Scholar 

  16. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus Infection. N Engl J Med 1993; 328: 465–470.

    Article  PubMed  CAS  Google Scholar 

  17. Matsumori A, Matoba Y, Sasayama S. Dilated Cardiomyopathy Associated with Hepatitis C Virus Infection. Circulation 1995; 92: 2519–2525.

    Article  PubMed  CAS  Google Scholar 

  18. Prati D, Poli F, Farma E, et al. Multicenter Study on Hepatitis C Virus Infection in Patients with Dilated Cardiomyopathy. J Med Virol 1999; 58: 116–120.

    Article  PubMed  CAS  Google Scholar 

  19. Dalekos GN, Achenbach K, Christodoulou D, et al. Idiopathic Dilated Cardiomyopathy: Lack of Association with Hepatitis C Virus Infection. Heart 1998; 80: 270–275.

    PubMed  CAS  Google Scholar 

  20. Matsumori A. Hepatitis C Virus and Cardiomyopathy. Intern Med 2001; 40: 78–79.

    Article  PubMed  CAS  Google Scholar 

  21. Matsumori A. Hepatitis C Virus Infection and Cardiomyopathy. Newsletter of the Scientific Council on Cardiomyopathies 2001; 16: 11–12.

    Google Scholar 

  22. Matsumori A, Matoba Y, Nishio R, et al. Detection of Hepatitis C Virus RNA from the Heart of Patients with Hypertrophic Cardiomyopathy. Biochem Biophys Res Commun 1996; 222: 678–682.

    Article  PubMed  CAS  Google Scholar 

  23. Matsumori A, Ohashi N, Nishio R, et al. Apical Hypertrophic Cardiomyopathy and Hepatitis C Virus Infection. Jpn Circ J 1999; 63: 433–438.

    Article  PubMed  CAS  Google Scholar 

  24. Matsumori A, Ohashi N, Hasegawa K, et al. Hepatitis C Virus Infection and Heart Diseases: A Multicenter Study in Japan. Jpn Circ J 1998; 62: 389–391.

    Article  PubMed  CAS  Google Scholar 

  25. Matsumori A, Furukawa Y, Hasegawa K, et al. Epidemiologic and Clinical Characteristics of Cardiomyopathies in Japan: Results from Nationwide Surveys. Cire J 2002; 66: 323–336.

    Article  Google Scholar 

  26. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A Molecular Basis for Familial Hypertrophic Cardiomyopathy: A Beta Cardiac Myosin Heavy Chain Gene Missense Mutation. Cell 1990; 62: 999–1006.

    Article  PubMed  CAS  Google Scholar 

  27. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the Genes for Cardiac Troponin T and Alpha-Tropomyosin in Hypertrophic Cardiomyopathy. N Engl J Med 1995; 332: 1058–1064.

    Article  PubMed  CAS  Google Scholar 

  28. Chimenti C, Calabrese F, Thiene G, et al. Inflammatory Left Ventricular Microaneurysms as a Cause of Apparently Idiopathic Ventricular Tachyarrhythmias. Circulation 2001; 104: 168–173.

    Article  PubMed  CAS  Google Scholar 

  29. Arai H, Tanaka M, Ohta K, et al. Symptomatic Myopathy Associated with Interferon Therapy for Chronic Hepatitis C. Lancet 1995; 345: 582.

    Article  PubMed  CAS  Google Scholar 

  30. Horsmans Y, Geubel AP. Symptomatic Myopathy in Hepatitis C Infection without Interferon Therapy. Lancet 1995; 345: 1236.

    Article  PubMed  CAS  Google Scholar 

  31. Ueno Y, Kondo K, Kidokoro N, et al. Hepatitis C Infection and Polymyositis. Lancet 1995; 346: 319–320.

    Article  PubMed  CAS  Google Scholar 

  32. Nishikai M, Miyairi M, Kosaka S. Dermatomyositis Following Infection with Hepatitis C Virus. J Rheumatol 1994; 21: 1584–1585.

    PubMed  CAS  Google Scholar 

  33. Nakamura K, Matsumori A, Kusano KF, et al. Hepatitis C Virus Infection in a Patient with Dermatomyositis and Left Ventricular Dysfunction. Jpn Circ J. 2000; 64: 617–618.

    Article  PubMed  CAS  Google Scholar 

  34. Sato Y, Takatsu Y, Yamada T, et al. Interferon Treatment for Dilated Cardiomyopathy and Striated Myopathy Associated with Hepatitis C Virus Infection Based on Serial Measurements of Serum Concentrations of Cardiac Troponin T. Jpn Circ J 2000; 64: 321–324.

    Article  PubMed  CAS  Google Scholar 

  35. Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C Virus Infection and Membranoproliferative Glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6: 220–223.

    PubMed  CAS  Google Scholar 

  36. Garcia-Valdecasas J, Bernai C, Garcia F, et al. Epidemiology of Hepatitis C Virus Infection in Patients with Renal Disease. J Am Soc Nephrol 1994; 5: 186–192.

    PubMed  CAS  Google Scholar 

  37. Matsumori A. Symposium on Clinical Aspects in Hepatitis Virus Infection. 5. Clinical Practice of Hepatitis: Myocardial Diseases, Nephritis, and Vasculitis Associated with Hepatitis Virus. Intern Med 2001; 40: 182–184.

    Article  PubMed  CAS  Google Scholar 

  38. Watanabe H, Ono T, Muso E, et al. Hepatitis C Virus Infection Manifesting as Tubulointerstitial Nephritis, Cardiomyopathy, and Hepatitis. Am J Med 2000; 109: 176–177.

    Article  PubMed  CAS  Google Scholar 

  39. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C Virus-Associated Glomerulonephritis. Effect of Alpha-Interferon Therapy. Kidney Int 1994; 46: 1700–1704.

    Article  PubMed  CAS  Google Scholar 

  40. Sarac E, Bastacky S, Johnson JP. Response to High-Dose Interferon-Alpha after Failure of Standard Therapy in MPGN Associated with Hepatitis C Virus Infection. Am J Kidney Dis 1997; 30: 113–115.

    Article  CAS  Google Scholar 

  41. Ursell PC, Habib A, Sharma P, et al. Hepatitis B Virus and Myocarditis. Hum Pathol 1984; 15: 481–484.

    Article  PubMed  CAS  Google Scholar 

  42. Mahapatra RK, Ellis GH. Myocarditis and Hepatitis B Virus. Angiology 1985; 36: 116–119.

    Article  PubMed  CAS  Google Scholar 

  43. Zarski JP, Bohn B, Bastie A, et al. Characteristics of Patients with Dual Infection by Hepatitis B and C Viruses. J Hepatol 1998; 28: 27–33.

    Article  PubMed  CAS  Google Scholar 

  44. Cacciola I, Pollicino T, Squadrito G, et al. Occult Hepatitis B Virus Infection in Patients with Chronic Hepatitis C Liver Disease. N Engl J Med 1999; 341: 22–26.

    Article  PubMed  CAS  Google Scholar 

  45. Congia M, Clemente MG, Dessi C, et al. HLA Class II Genes in Chronic Hepatitis C Virus-Infection and Associated Immunological Disorders. Hepatology 1996; 24: 1338–1341.

    Article  PubMed  CAS  Google Scholar 

  46. Naruse T, Inoko H. HLA and Hepatitis C Virus Positive Cardiomyopathy. Nippon Rinsho 2000; 58: 212–217.

    PubMed  CAS  Google Scholar 

  47. Matsumori A, Yutani C, Ikeda Y, et al. Hepatitis C Virus from the Hearts of Patients with Myocarditis and Cardiomyopathy. Lab Invest 2000; 80: 1137–1142.

    Article  PubMed  CAS  Google Scholar 

  48. Rullier A, Trimoulet P, Urbaniak R, et al. Immunohistochemical Detection of HCV in Cirrhosis, Dysplastic Nodules, and Hepatocellular Carcinomas with Parallel-Tissue Quantitative RT-PCR. Mod Pathol 2001; 14: 496–505.

    Article  PubMed  CAS  Google Scholar 

  49. Matsumori A, Kawai C, Yamada T, et al. Mechanism and Significance of Myocardial Uptake of Antimyosin Antibody in Myocarditis and Cardiomyopathy: Clinical and Experimental Studies. Clin Immunol Immunopathol 1993; 68: 215–219.

    Article  PubMed  CAS  Google Scholar 

  50. Ooyake N, Kuzuo H, Hirano H, et al. Myocardial Injury Induced by Hepatitis C Virus and Interferon Therapy. Presented at the 96th annual scientific meeting of the Japanese Society of Internal Medicine, Tokyo, 1999.

    Google Scholar 

  51. Sato Y, Yamada T, Taniguchi R, et al. Persistently Increased Serum Concentrations of Cardiac Troponin T in Patients with Idiopathic Dilated Cardiomyopathy are Predictive of Adverse Outcomes. Circulation. 2001; 103: 369–374.

    Article  PubMed  CAS  Google Scholar 

  52. Sato Y, Kataoka K, Matsumori A, et al. Measuring Serum Aminoterminal Type III Procollagen Peptide, 7S Domain of Type IV Collagen, and Cardiac Troponin T in Patients with Idiopathic Dilated Cardiomyopathy and Secondary Cardiomyopathy. Heart 1997; 78: 505–508.

    PubMed  CAS  Google Scholar 

  53. Suzuki H, Matsumori A, Matoba Y, et al. Enhanced Expression of Superoxide Dismutase Messenger RNA in Viral Myocarditis. An SH-Dependent Reduction of Its Expression and Myocardial Injury. J Clin Invest 1993; 91: 2727–2733.

    Article  PubMed  CAS  Google Scholar 

  54. Tanaka A, Matsumori A, Wang W, et al. An Angiotensin II Receptor Antagonist Reduces Myocardial Damage in an Animal Model of Myocarditis. Circulation 1994: 90: 2051–2055.

    Article  PubMed  CAS  Google Scholar 

  55. Tominaga M, Matsumori A, Okada I, et al. Beta-Blocker Treatment of Dilated Cardiomyopathy. Beneficial Effect of Carteolol in Mice. Circulation 1991; 83: 2021–2028.

    Article  PubMed  CAS  Google Scholar 

  56. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant Interferon Alfa Therapy for Chronic Hepatitis C. A Randomized, Double-Blind, Placebo-Controlled Trial. N Engl J Med 1989; 321: 1506–1510.

    Article  PubMed  Google Scholar 

  57. Davis GL, Balart LA, Schiff ER, et al. Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa. A Multicenter Randomized, Controlled Trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501–1506.

    Article  PubMed  CAS  Google Scholar 

  58. Cohen MC, Huberman MS, Nesto RW. Recombinant Alpha 2 Interferon-Related Cardiomyopathy. Am J Med 1988; 85: 549–551.

    Article  PubMed  CAS  Google Scholar 

  59. Sonnenblick M, Rosin A. Cardiotoxicity of Interferon. Chest 1991; 99: 557–561.

    Article  PubMed  CAS  Google Scholar 

  60. Matsumori A, Wang H, Abelmann WH, et al. Treatment of Viral Myocarditis with Ribavirin in an Animal Preparation. Circulation 1985; 71: 834–839.

    Article  PubMed  CAS  Google Scholar 

  61. Okada I, Matsumori A, Matoba Y, et al. Combination Treatment with Ribavirin and Interferon for Coxsackievirus B3 Replication. J Lab Clin Med 1992; 120: 569–573.

    PubMed  CAS  Google Scholar 

  62. Matsumori A, Okada I, Kawai C, et al. “Animal Models for Therapeutic Trials of Viral Myocarditis: Effect of Ribavirin and Alpha Interferon on Coxsackievirus B3 and Encephalomyocarditis Virus Myocarditis.” In: New Concepts in Viral Heart Disease. Schultheiss HP, ed. Berlin: Springer-Verlag, 1988.

    Google Scholar 

  63. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. N Engl J Med 1998; 339: 1493–1499.

    Article  PubMed  CAS  Google Scholar 

  64. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. N Engl J Med 1998; 339: 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  65. Poynard T, Marcellin P, Lee SS, et al. Randomised Trial of Interferon Alpha-2b Plus Ribavirin for 48 Weeks or for 24 Weeks Versus Interferon Alpha-2b Plus Placebo for 48 Weeks for Treatment of Chronic Infection with Hepatitis C Virus. Lancet 1998; 352: 1426–1432.

    Article  PubMed  CAS  Google Scholar 

  66. Booth JCL, O’Grady JO, Neuberger J. Clinical Guidelines on the Management of Hepatitis C. Gut 2001; 49: 11–121.

    Article  Google Scholar 

  67. Izopet J, Payen JL, Alric L, et al. Baseline Level and Early Suppression of Serum HCV RNA for Predicting Sustained Complete Response to Alpha-Interferon Therapy. J Med Virol 1998; 54: 86–91.

    Article  PubMed  CAS  Google Scholar 

  68. Bellobuono A, Mondazzi L, Tempini S, et al. Should Patients with Early Loss of Serum HCV-RNA During Alpha Interferon Therapy for Chronic Hepatitis C be Treated for 6 or 12 Months? J Hepatol 1999; 30: 8–13.

    Article  PubMed  CAS  Google Scholar 

  69. Gale MJ, Korth MJ, Tang NM, et al. Evidence that Hepatitis C Virus Resistance to Interferon is Mediated through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein. Virology 1997; 230: 217–227.

    Article  PubMed  CAS  Google Scholar 

  70. Taylor DR, Shi ST, Romano PR, et al. Inhibition of the Interferon-Inducible Protein Kinase PKR by HCV E2 Protein. Science 1999; 285: 107–110.

    Article  PubMed  CAS  Google Scholar 

  71. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the Nonstructural Protein 5A Gene and Response to Interferon in Patients with Chronic Hepatitis C Virus lb Infection. N Engl J Med 1996; 334: 77–81.

    Article  PubMed  CAS  Google Scholar 

  72. Marusawa H, Hijikata M, Chiba T, et al. Hepatitis C Virus Core Protein Inhibits Fas-and Tumor Necrosis Factor Alpha-Mediated Apoptosis Via NF-kappaB Activation. J Virol 1999; 73: 4713–4720.

    PubMed  CAS  Google Scholar 

  73. Zhu N, Khoshnan A, Schneider R, et al. Hepatitis C Virus Core Protein Binds to the Cytoplasmic Domain of Tumor Necrosis Factor (TNF) Receptor 1 and Enhances TNF- Induced Apoptosis. J Virol 1998; 72: 3691–3697.

    PubMed  CAS  Google Scholar 

  74. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of Hepatitis C Virus to CD81. Science 1998; 282: 938–941.

    Article  PubMed  CAS  Google Scholar 

  75. Kolykhalov AA, Mihalik K, Feinstone SM, et al. Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3’ Nontranslated Region are Essential for Virus Replication In Vivo. J Virol 2000; 74: 2046–2051

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine , Graduate School of Medicine, Kyoto University, 54 Kawaracho Shogoin Sakyo-ku, Kyoto, 606-8397, Japan

    Yukihito Sato MD, PhD, Tasuku Yamada MD & Akira Matsumori MD, PhD

Authors
  1. Yukihito Sato MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tasuku Yamada MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Matsumori MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Akira Matsumori MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sato, Y., Yamada, T., Matsumori, A. (2003). Hepatitis Cvirus and Cardiomyopathy. In: Matsumori, A. (eds) Cardiomyopathies and Heart Failure. Developments in Cardiovascular Medicine, vol 248. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9264-2_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9264-2_25

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4865-8

  • Online ISBN: 978-1-4419-9264-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation